New hope for tough kidney cancers: Head-to-Head drug battle begins
NCT ID NCT05012371
Summary
This study compares two different drug treatments for people with advanced kidney cancer that has spread and continued to grow despite previous immunotherapy. Researchers want to see whether a combination of two drugs (lenvatinib plus everolimus) works better than a single drug (cabozantinib) at slowing cancer progression. The trial will involve about 90 patients whose cancer worsened after 1-2 prior treatments including immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.